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Herpes simplex virus (HSV) immediate-early protein ICP27 is a multifunctional regulator of viral and cellular gene
expression. It has previously been shown that ICP27 directly or indirectly modulates several posttranscriptional processes,
such as pre-mRNA splicing and polyadenylation. We show here that pre-mRNA splicing is inhibited in nuclear extracts
prepared from cells in which ICP27 has been transiently expressed. Our results show that splicing inhibition in ICP27 extracts
is manifested at early stages of the splicing process. Furthermore, our results suggest that an enzymatic activity in© 2002 E
.INTRODUCTION
Herpes simplex virus (HSV) is a nuclear replicating
DNA virus that encodes approximately 80 proteins. The
HSV genes are expressed in a temporal cascade in
which the immediate-early (IE) genes are expressed first,
followed by the expression of the early (E) and late (L)
genes. Lytic HSV infection involves a series of transcrip-
tional and posttranscriptional processes, resulting in a
sequential activation and repression of IE, E, and L
genes and in an almost complete shutoff of host cell
gene expression. Contrary to cellular protein coding
genes only 4 of approximately 80 HSV genes contain
introns (reviewed in Roizman and Sears (1996)).
ICP27 is an IE protein that is essential for productive
HSV infection in cultured cells (Sacks et al., 1985). HSV
mutants with defective or absent ICP27 proteins express
reduced levels of some E and most L mRNAs and are
defective in viral DNA replication (McCarthy et al., 1989;
McMahan and Schaffer, 1990; Rice and Knipe, 1990).
During a lytic HSV infection host cell gene expression is
drastically reduced and a considerable amount of data
has suggested that ICP27 causes the shutoff of cellular
gene expression by inhibiting pre-mRNA splicing: cellu-
lar gene expression is not suppressed in the presence of
mutant ICP27 (Hardwicke and Sandri-Goldin, 1994;
Phelan et al., 1993). Since the majority of HSV genes do
not contain introns, HSV gene expression would be rel-
atively resistant to the splicing inhibition. The mecha-
nism(s) by which ICP27 carries out its different activities
is largely unknown. However, a large number of studies
1189have demonstrated that at least some, if not most, of its
effects on gene expression occur at the posttranscrip-
tional level. For instance, studies have demonstrated that
ICP27 can modulate the pre-mRNA polyadenylation effi-
ciency (McGregor et al., 1996; McLauchlan et al., 1992),
promote nucleocytoplasmic export of intronless HSV
genes (Sandri-Goldin, 1998a), increase the stability of
labile mRNAs (Brown et al., 1995), and change the in-
tranuclear distribution of pre-mRNA splicing factors
(Phelan et al., 1993; Sandri-Goldin et al., 1995) and it has
also been proposed to inhibit pre-mRNA splicing (Hardy
and Sandri-Goldin, 1994; Sandri-Goldin and Mendoza,
1992). Also, ICP27 has been reported to coimmunopre-
cipitate with splicing factors (Sandri-Goldin, 1998b; San-
dri-Goldin and Hibbard, 1996) and to alter the phosphor-
ylation status of some of these proteins (Sandri-Goldin
and Hibbard, 1996). Finally, ICP27 has been shown to
have RNA-binding activity and to continuously shuttle
between the nucleus and the cytoplasm (Ingram et al.,
1996; Phelan and Clements, 1997; Sandri-Goldin, 1998a;
Soliman et al., 1997).
We here present a cell-free in vitro splicing system that
allows studies of ICP27-caused splicing inhibition. The
system is based on splicing of exogenous pre-mRNAs in
nuclear extracts which are prepared from cells in which
ICP27 has been transiently expressed. Results from our
studies using this system show that pre-mRNA splicing
activity is drastically reduced in nuclear extracts pre-
pared from ICP27-expressing cells compared to control
extracts. The specificity of the ICP27-caused splicing
inhibition was supported by the fact that RNA polymer-
ase II activities in nuclear extracts from both ICP27-
containing and control cells were comparable. We foundICP27-containing extracts causes the splicing inhibition.
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versed by addition of nuclear extracts from control cells,
suggesting that only one or a few essential splicing
factors are repressed. Furthermore, we find that the
splicing inhibition is manifested at early stages of spli-
ceosome formation, which suggests that splicing factors
involved in the initial stages of the process are hampered
in the presence of ICP27. Finally, we present data show-
ing that the ICP27-mediated splicing inhibition can, at
least partly, be transferred to splicing-competent nuclear
extracts upon preincubation at 30°C, indicating that
ICP27-containing extracts are associated with an enzy-
matic activity that results in splicing inhibition.
RESULTS
Expression of ICP27 in HeLa cells using recombinant
adenovirus vector
In order to establish a reproducible method to tran-
siently express HSV ICP27 protein in cell cultures we
constructed a recombinant adenovirus encoding the pro-
tein. The adenovirus E1A and E1B genes were replaced
with ICP27-coding sequences under tight control of a
CMV progesterone promoter and a lac-repressor ele-
ment (see Materials and Methods for details). The result-
ing virus, Ad5-ICP27, cannot replicate in HeLa cells since
the viral proteins from the E1A and E1B regions are
essential for efficient expression of other viral genes and
for viral DNA replication. HeLa cells were infected with
the Ad5-ICP27 virus and an activator virus encoding a
chimeric transactivator protein containing the ligand-
binding domain of hPRB891 fused to the Gal4 DNA-
binding domain and the HSV VP16 transactivator domain
(Molin et al., 1998). At the onset of infection, ICP27
expression was specifically induced by addition of
RU486, a progesterone antagonist. After 24 or 48 h of
RU486 induction, HeLa cells were harvested and soluble
cytoplasmic and nuclear protein extracts were prepared.
We next analyzed the presence of ICP27 using Western
blot assay with an ICP27-specific antibody. As shown in
Fig. 1A, at 24 h after RU486 induction ICP27 is detected
in both the cytoplasmic and the nuclear fractions of HeLa
cells. An additional 24 h of induction did not markedly
increase ICP27 levels (FIg. 1A, 48 hpi). As expected, no
ICP27 could be detected in mock-infected cells (Fig. 1A,
HeLa NE), demonstrating the specificity of the Western
blot assay. Notably, the majority of soluble ICP27 was
recovered in the cytoplasmic fraction (Fig. 1A, compare
lanes C and N). Numerous previously published studies
on ICP27 have indicated that at steady state it is pre-
dominantly a nuclear protein (Ackermann et al., 1984;
Knipe et al., 1987; Mears and Rice, 1998; Phelan et al.,
1993; Sandri-Goldin, 1998b; Soliman et al., 1997). One
possible explanation for the discrepancy between our
results and previously published observations was that
our cytoplasmic extracts became contaminated with nu-
clear proteins during cell fractionation. To test this hy-
pothesis we analyzed the distribution of p99 in our cell
extracts. p99 is an almost exclusively nuclear protein in
interphase cells and its presence in the cytoplasmic
fraction would therefore be an indicator of nuclear con-
tamination (Kreivi et al., 1997). The nitrocellulose filter
that originally was probed with ICP27 antibodies (Fig. 1A)
was stripped and reprobed with p99-specific antibodies.
As seen in Fig. 1B, the vast majority of p99 was detected
in the nuclear fractions, with no detectable p99 in cyto-
plasmic extracts prepared from 24-hpi cells and only low
levels of p99 in cytoplasmic extracts from cells that had
been induced for 48 h (Fig. 1B). Thus, the presence of
ICP27 in the cytoplasmic fraction is probably not the
result of nuclear contamination of the cytoplasmic ex-
tract. Possible explanations for the discrepancy between
our results and the majority of previously published re-
sults regarding ICP27’s cellular distribution are pre-
sented elsewhere (see Discussion). Collectively these
results show that ICP27 is readily expressed from Ad5-
ICP27 in HeLa cells and under the conditions in which
the cytoplasmic and nuclear extracts were prepared,
most of the soluble pool of ICP27 was present in the
cytoplasmic fraction (see Discussion for more details on
ICP27 distribution and solubility).
Splicing is inhibited in nuclear extracts prepared from
ICP27-expressing cells
To determine the effect of ICP27 on the pre-mRNA
splicing process, we compared splicing activity in ICP27-
containing nuclear extracts with the activity in extracts
prepared from mock-infected cells. Two different 32P-
labeled pre-mRNA substrates, a -globin pre-mRNA and
an adenovirus derived pre-mRNA, were incubated under
in vitro splicing conditions in the two types of extracts. As
shown in Fig. 2A, -globin and adenovirus pre-mRNAs
were efficiently spliced in nuclear extracts prepared from
mock-infected HeLa cells (lanes 1 and 4). The nuclear
extracts prepared from ICP27-expressing cells, on the
other hand, possessed low, if any, splicing activity (Fig.
FIG. 1. ICP27 expression from recombinant adenovirus Ad5-ICP27.
HeLa cells were either infected with Ad5-ICP27 or mock-infected, and
ICP27 expression was induced for 24 or 48 h. Cells were harvested and
fractionated into cytoplasmic (C, lanes 1 and 3) and nuclear (N, lanes
2, 4, and 5) extracts. Proteins were analyzed by SDS–PAGE and immuno-
blotting with either -ICP27 antibodies (A) or -p99 antibodies (B),
using an ECL detection assay.
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2A, lanes 3 and 6). The input pre-mRNAs were stable in
ICP27 extracts during the course of the experiments,
arguing that the decreased levels of splicing products
and intermediates are not likely to be the result of in-
creased RNA degradation. In order to test whether splic-
ing could be initiated in the presence of ICP27, the
splicing-competent control extracts were mixed with
ICP27-containing extracts at a 1:1 ratio and immediately
analyzed for splicing activity. As shown in Fig. 2A, the
addition of splicing-competent extracts to the ICP27-
containing nuclear extracts completely restored splicing
(Fig. 2A, compare lanes 2 and 3 and lanes 5 and 6). The
-globin and adenovirus pre-mRNAs were at least as
efficiently spliced in mixed extracts as in control extracts:
a quantification of the gels presented in Fig. 2A demon-
strated that the -globin pre-mRNA was 10% more effi-
ciently spliced in the mixed extracts than in the control
extracts and that the adenovirus pre-mRNA was equally
well spliced in mixed and control extracts. In identical
mixing experiments we have noted that splicing is nota-
bly activated in several batches of ICP27-containing nu-
clear extracts when complemented with control extracts
at a 1:3 ratio (data not shown), suggesting that the overall
quality of the ICP27 extracts is good and that only a few
components of the splicing machinery are targeted by
ICP27 (discussed in more detail under Discussion). The
experiments presented in Fig. 2A have been repeated
several times using different preparation of ICP27 ex-
tracts and, although there is some variability in the de-
gree of inhibition, we have consistently observed an
80–100% reduction in splicing activity in ICP27 extracts
compared to the control extract, which was used in all
experiments presented here except Fig. 2B.
In order to confirm that it was expression of ICP27 that
causes the splicing observation presented in Fig. 2A, we
prepared nuclear extracts from uninduced or RU486-
induced HeLa cells that had been infected with Ad5-
ICP27. The cells were otherwise treated identically and
the nuclear extracts were prepared in parallel. An immu-
noblotting analysis of the resulting extracts confirmed
that only low levels of ICP27 were expressed in the
uninduced cells, whereas ICP27 was abundant in the
extracts from RU486-induced cells (data not shown). We
next compared splicing activity in the nuclear extracts
from RU486-induced cells or uninduced cells. As shown
in Fig. 2B, RU486 induction (and thus ICP27 expression)
caused a dramatic reduction of splicing activity in the
resulting extracts. Although the splicing activity in the
extracts from the uninduced cells was relatively low
compared to the HeLa extracts used in Fig. 2A (lanes 1
and 4), it was substantially higher than that in the ICP27-
containing extracts that were prepared in parallel (com-
pare lanes  and  in Fig. 2B). Moreover, we did not
observe any dramatic reduction in splicing activity in
nuclear extracts prepared from HeLa cells expressing
chloramphenicol acetyltransferase from an identical re-
combinant adenovirus vector (data not shown). From
these results we conclude that the negative effect of
ICP27 on splicing is not due to toxicity from the virus
infection as such or to protein overexpression.
We next sought to test whether the reduced splicing
activity observed in ICP27 extracts was specific for the
splicing process. For this purpose we analyzed the ac-
tivity of another nuclear process in ICP27 extracts and
control extracts: RNA polymerase II transcription. A DNA
fragment containing the adenovirus major late promoter
was incubated together with -32P-labeled CTP in ICP27
extracts or control extracts under conditions optimal for
RNA polymerase II transcription. We analyzed RNA poly-
merase II activity in different preparations of nuclear
extracts from ICP27-expressing cells and mock-infected
cells. As can be seen in Fig. 2C, no significant differ-
ences in RNA polymerase II activity in the different prep-
arations of extracts were detected. Importantly, RNA
FIG. 2. Comparison of in vitro splicing and RNA polymerase II
activities in ICP27-containing extracts and HeLa mock extracts. (A) In
vitro splicing reactions using 32P-labeled Ad1 and -globin pre-mRNA
as substrates were performed for 1 h in nuclear extracts prepared from
mock-infected HeLa cells and from ICP27-expressing HeLa cells. In-
dicated amounts of ICP27-containing nuclear extracts and control ex-
tracts were used in the splicing reactions. The position of pre-mRNA
and the various splice products are indicated on the sides. (B) In vitro
splicing of a -globin pre-mRNA substrate in nuclear extracts prepared
from HeLa cells infected with the ICP27 expressing recombinant ade-
novirus Ad5-ICP27. ICP27 expression was either induced () with
RU486 or not (). (C) RNA polymerase II reactions were performed in
nuclear extracts under optimal conditions in the presence of -32P-
labeled CTP and a DNA fragment containing the adenovirus major late
promoter. The expected size of the RNA polymerase II product is
indicated on the right.
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polymerase II activity in ICP27-containing extracts was
not lower than that in extracts from mock-infected cells.
Taken together, the RNA polymerase II assay confirms
that the splicing inhibition observed in ICP27 extracts is
specific, rather than a general toxic effect of an overex-
pressed protein.
ICP27 inhibits splicing at early stages
of spliceosome assembly
We next sought to determine at which stage of the
splicing process the negative effect of ICP27 is first
manifested. Mechanistically, pre-mRNA splicing is a two-
step reaction which is catalyzed in a ribonucleoprotein
complex called the spliceosome (reviewed in Burge et al.
(1998)). Besides pre-mRNA, spliceosomes contain U
snRNP particles and non-snRNP splicing factors. In vitro,
spliceosomes are formed in a stepwise manner where
the E complex is the first discrete functional spliceoso-
mal complex. It contains U1 snRNP and several other
non-snRNP splicing factors, which associate with the
pre-mRNA in an energy-independent manner. The E
complex is converted into the pre-spliceosomal A com-
plex after ATP hydrolysis and addition of U2 snRNP.
Following additional ATP hydrolysis, U4/U6.U5 snRNP is
added to A complex and thereby converts it into the
prespliceosome B complex. After further ATP hydrolysis
and rearrangements within the B complex, the C com-
plex is formed, which is the mature spliceosome in which
the two catalytic steps of splicing are catalyzed. The
assembly of pre-mRNA into spliceosomal complexes A,
B, and C, but not E complex, can be studied in vitro by
separating splicing reactions using native polyacryl-
amide gel electrophoresis. The A, B, and C complexes
have different kinetics and they separate into three rel-
atively distinct units during electrophoresis (Fig. 3A). The
E complex, however, is “hidden” within the nonspecific H
complex and can therefore not be distinguished using
this assay. The exact nature of the H complex is not
clear. Besides the E complex, the H complex also con-
tains RNA–protein complexes that are not functional spli-
ceosome precursors. In an attempt to identify the mech-
anism by which splicing is inhibited in ICP27 extracts we
compared spliceosome assembly kinetics in ICP27 ex-
tracts with that in control extracts. A 32P-labeled pre-
mRNA was incubated under in vitro splicing conditions in
ICP27 extracts and control extracts, and at various time
points the splicing reactions were stopped and the sam-
ples were divided into two halves. One half was analyzed
for spliceosome formation and from the other half RNA
was isolated and analyzed for splicing products. As
shown in Fig. 3A, splicing complexes A, B, and C are
readily formed in control extracts from mock-infected
HeLa cells. The splicing catalytic C complex was already
detected in control extracts after 15 min of incubation
(Fig. 3A, lane 2). In agreement with this, RNA products
from the first catalytic splicing step were observed at this
time point (Fig. 3B, lane 2). It is also noteworthy that the
amounts of prespliceosomal A and B complexes in con-
trol extracts started to decline between 15 and 30 min of
incubation, whereas the amount of C complex continued
to accumulate for up to 30 min of incubation (Fig. 3A,
lanes 1–4; a quantitative analysis of the gel is presented
in Fig. 3C). In ICP27-containing extracts, however, quite a
different picture emerged. Although the amount of A
complex was as abundant in ICP27 extracts as in control
extracts after 15 min of incubation, substantially less B
complex and hardly any C complex had formed in ICP27
extracts at this time point (Fig. 3A, lanes 2 and 6 and
filled circles in Fig. 3C). After 30 min of incubation in
ICP27 extracts the level of B complex was higher than in
control extracts (Fig. 3C). The B complex continued to
accumulate in ICP27 extracts through the course of in-
cubation, whereas in control extracts the amount of B
complex peaked around 30 min. A probable explanation
for the differences in kinetics is that B complex is more
FIG. 3. Analysis of splicing complex formation in ICP27-containing
extracts. In vitro splicing reactions were performed in ICP27-containing
nuclear extracts and control extracts using 32P-labeled Ad1 pre-mRNA
as substrate. At indicated time points samples were withdrawn and
directly analyzed for spliceosome formation using native polyacryl-
amide gel electrophoresis (A), or RNA was isolated and production of
splicing products was analyzed using denaturing polyacrylamide gel
electrophoresis (B). The positions of the different splicing complexes
are indicated on left-hand side of A and splicing products are indicated
on the right-hand side of B. (C) The quantitative results of the relative
accumulation of the spliceosomal complexes A, B, and C in panel (A).
The relative accumulation is expressed as the percentage of total RNA
in each lane. Filled circles represent complexes formed in ICP27 extracts
and hollow boxes represent complexes formed in control extracts.
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efficiently converted into C complex in control extracts as
compared to ICP27 extracts. In support of this we note
that the largest differences in formation of spliceosomal
complexes between ICP27 extracts and control extracts
appears to be in the rate at which C complexes are
formed (Fig. 3C). As expected, the slower formation of C
complex in ICP27 extracts was accompanied by reduced
accumulation of splicing products (Fig. 3B, compare
lanes 2 to 4 with lanes 6 to 8). Splicing products are
readily observed after 15 min of incubation in control
extracts, but it takes more than 30 min of incubation in
ICP27 extracts in order for detectable amounts of splic-
ing intermediates to be produced (Fig. 3B, lane 8). In
separate experiments, using incubation times shorter
than 15 min, we have noticed that the rate of A complex
formation is also slower in ICP27 extracts than in control
extracts (data not shown), thus demonstrating an effect
by ICP27 on early stages of spliceosome assembly. In
addition to the differences in the rates at which the
different spliceosomal complexes are formed, we note
that the A complex formed in ICP27 extracts consistently
migrates notably faster than A complex formed in control
extracts (Fig. 3A, compare lanes 2 to 4 with lanes 6 to 8).
Also, although it is not as obvious as for the A complex,
there is a clear tendency for H and B complexes formed
in ICP27 extracts to migrate faster than their counter-
parts formed in control extracts. The faster mobility of the
RNA–protein complexes formed in ICP27 extracts could
reflect a qualitative and/or a quantitative difference be-
tween these and their counterparts formed in control
extracts. We note that the protein concentrations in the
various ICP27 extracts and control extracts are compa-
rable (data not shown). It is therefore unlikely that the
faster mobility of RNA–protein complexes formed in ICP27
extracts result from lower concentrations of splicing factors
and other RNA-binding proteins. We are currently investi-
gating whether the different mobilities of spliceosomal
complexes formed in ICP27 extracts and control extracts
reflect a qualitative difference between prespliceosomes
and spliceosomes. In summary, the results presented in
Fig. 3 combined with results from a similar experiment
show that the reduced splicing rate in ICP27 extracts is
manifested already at the formation of the first energy-
dependent prespliceosome complexes (A and B com-
plexes). Moreover, they show that the rates in which A
complex is converted to B, B complex to C complex, and
C complex to splicing products are all reduced in ICP27
extracts. However, the largest difference between ICP27
extracts and control extracts appears to be the rate at
which C complexes, i.e., mature spliceosomes, are formed.
ICP27’s splicing inhibitory activity can be transferred
to splicing-competent nuclear extracts
It has previously been reported that splicing activity in
nuclear extracts prepared from HSV-infected HeLa cells
is reduced compared to splicing in extracts isolated from
cells infected with an ICP27 viral mutant (Hardy and
Sandri-Goldin, 1994). Furthermore, in the same report it
was shown in biochemical complementation assays that
HSV-caused splicing inhibition could be transferred to
otherwise splicing-competent extracts in a dominant
way. Contrary to this, we found that a 1:1 mixture of
ICP27 extracts and control extracts was sufficient to fully
restore splicing (Fig. 2A, lanes 2 and 4). In these exper-
iments the extracts were mixed on ice and immediately
used in splicing assays. Thus, it was possible that a
putative trans-dominant effect of ICP27 did not have time
to act on the splicing machinery in control extracts be-
fore the splicing process had initiated. We therefore
redesigned the complementation experiments in order to
test whether the splicing inhibitory activity in ICP27 ex-
tracts could be transferred to otherwise splicing-compe-
tent extracts. The splicing-competent control extracts
were mixed with ICP27 extracts at a 1:1 ratio and incu-
bated at 30°C for various times or on ice for 2 h. At the
end of the preincubation, splicing was initiated by addi-
tion of 32P-labeled pre-mRNA, magnesium, creatine
phosphate, and ATP. As shown in Fig. 4, the amount of
spliced mRNA was reduced in mixed extracts that had
been preincubated for 1 h at 30°C (compare lanes 1 and
3). Also, the negative effect of ICP27 extracts on control
extracts was enhanced with time of preincubation at
30°C (Fig. 4, compare lane 1 with lanes 3–7). Splicing
was substantially less reduced in mixed extracts that
had been preincubated on ice (Fig. 4, lane 8). Splicing
activity in nuclear extracts from mock-infected cells was
also reduced upon preincubation at 30°C (Fig. 4, com-
pare lanes 1 and 2), but the reduction was not as large as
in mixed extracts. Note that although the lariat splicing
intermediate intron–exon 2 and the spliced-out intron did
not separate well in the experiment presented in Fig. 4,
quantitative analyses of this and similar experiments
demonstrate that splicing is inhibited before the first
catalytic step also in the preincubated mixed extracts
(data not shown). These results taken together indicate
that a dominant splicing inhibitory activity is present in
ICP27 extracts and that this activity requires time and
30°C to accomplish the inhibition.
DISCUSSION
In this study we present an assay in which ICP27-
caused splicing inhibition for the first time is studied in
vitro in the absence of other HSV proteins. A large body
of evidence has supported the notion that ICP27 inhibits
splicing (Hardwicke and Sandri-Goldin, 1994; Hardy and
Sandri-Goldin, 1994; Sandri-Goldin and Mendoza, 1992;
Soliman et al., 1997). For instance, nuclear extracts from
HSV-infected HeLa cells have lower splicing activity than
extracts isolated from cells infected with ICP27 null mu-
tants (Hardy and Sandri-Goldin, 1994), ICP27 coimmuno-
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precipitates with various splicing factors (Sandri-Goldin,
1998b; Sandri-Goldin and Hibbard, 1996), and ICP27 re-
distributes splicing factors in nuclei of infected cells
(Phelan et al., 1993; Sandri-Goldin et al., 1995). However,
direct evidence for a splicing inhibitory function of ICP27
in the absence of other viral proteins has been lacking. In
order to study the putative splicing inhibitory activity of
ICP27, we constructed a eukaryotic expression system
based on a recombinant adenovirus which would allow
us to express relatively large amounts of the protein in
HeLa spinner cells. We found that ICP27 was readily
expressed in HeLa cells and although a substantial por-
tion of ICP27 was recovered from nuclei, more of the
protein was present in a soluble cytoplasmic cell frac-
tion. In contrast to this finding, many previously pub-
lished studies have shown that although ICP27 is con-
tinuously shuttling between the nucleus and the cyto-
plasm, the nuclear steady state levels of the protein are
substantially higher than the cytoplasmic levels (Acker-
mann et al., 1984; Knipe et al., 1987; Mears and Rice,
1998; Phelan et al., 1993; Sandri-Goldin, 1998b; Soliman
et al., 1997). The predominant nuclear localization of
ICP27 has been observed both for ICP27 transiently
expressed from plasmid DNA and for ICP27 expressed
during lytic HSV infections. However, there is a prece-
dence for cytoplasmic enrichment of ICP27 too: using a
cell fractionation assay Wilcox et al. (1980) found that
ICP27 is evenly distributed between the nucleus and the
cytoplasm during a virus infection. In the same study it
was demonstrated that the cytoplasmic pool of ICP27 is
much more soluble in 0.15 M NaCl than ICP27 isolated
from nuclei. They found that almost all ICP27 in the
nuclear extracts precipitated upon dialysis from high-salt
(0.5 M NaCl) to low-salt (0.15 M NaCl) buffer, whereas
cytoplasmic ICP27 largely remained soluble upon an
identical change in salt concentration. The nuclear and
cytoplasmic extracts that we used in this study were
prepared and treated in a similar way; the HeLa cell
nuclei were extracted at 0.3 M KCl and the resulting
extracts were dialyzed to 0.1 M KCl. It is thus likely that
the majority of ICP27 originally present in our nuclear
extract preparations precipitated during dialysis. From
this follows that in the assay, which is presented in Fig.
1, we compare the soluble pool of ICP27 in the nucleus
and cytoplasm. If a large portion of nuclear ICP27 actu-
ally is insoluble under the conditions used for nuclear
extract preparation, the result would be an overestima-
tion of cytoplasmic versus nuclear distribution of ICP27.
In this context it is worth mentioning that we have com-
pared the concentration of various splicing factors in
nuclear extracts from ICP27-expressing cells with con-
trol extracts, without detecting any consistent or major
quantitative differences with the two types of extracts
(Fig. 1B; and data not shown).
In a second part of this study we analyzed the effect of
ICP27 on splicing in vitro. Taken together, the data from
these studies strongly suggest that the presence of
ICP27, in the absence of other HSV proteins, causes a
general inhibition of splicing. The fact that a small
amount of splicing-competent control extracts were able
to substantially activate splicing to ICP27 extracts sug-
gests that an essential splicing factor that is limiting
for the process is hampered in ICP27 extracts, rather
than causing major damage to the entire splicing
machinery.
How then is splicing inhibited in the presence of
ICP27? Our results show that the formation of all energy-
dependent spliceosome complexes was delayed in
ICP27 extracts as compared to control extracts; the rates
at which A complex is converted into B complex, and B
complex to C complex, were notably slower in ICP27
extracts than in control extracts. It was also apparent that
different RNA–protein complexes formed in ICP27 ex-
tracts migrated notably faster during electrophoresis
than their counterparts formed in control extracts. In
particular, H, A, and B complexes formed in ICP27 ex-
FIG. 4. Effect on in vitro splicing after mixing and preincubating
ICP27-containing nuclear extracts with extracts from mock-infected
HeLa cells. (A) ICP27 extracts were mixed with HeLa extracts (lanes 3
to 8). The samples in lanes 2 to 7 were incubated at 30°C for the
indicated times (in minutes) and the sample in lane 8 was incubated on
ice for 2 h. 32P-labeled Ad1 pre-mRNA and ATP were added at the end
of preincubation and splicing was allowed to proceed for 1 h before
RNA was extracted and analyzed using denaturing polyacrylamide gel
electrophoresis. The positions of the pre-mRNA and the various splice
products are indicated on the right. Note that in this particular exper-
iment the splicing intermediate intron–lariat–exon 2 and the splicing
product intron–lariat did not separate well during electrophoresis. (B)
The relative splicing efficiencies in A were quantitated using a phos-
phorimager as described under Materials and Methods.
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tracts migrate faster than those assembled in control
extracts. It is very likely that the altered mobility reflects
a qualitative and/or a quantitative difference between the
splicing complexes formed in the two types of extracts;
one or more splicing factors may be missing or present
in smaller amounts in the splicing complexes formed in
ICP27 extracts. Another possibility is that ICP27 causes
modification of specific splicing factors and that this in
turn could impair the splicing factor’s ability to participate
in spliceosome formation and/or destabilize its interac-
tion with other splicing factors. In support of this hypoth-
esis we found that ICP27 extracts indeed possessed a
dominant splicing inhibitory activity. The dominant inhib-
itory activity in ICP27 could be transferred to splicing-
competent control extracts only if the two extracts were
preincubated at 30°C, and the inhibition increased with
time (Fig. 4). These results suggest that an enzymatic
activity in ICP27-containing extract targets an essential
component(s) of the splicing machinery. In this context it
is interesting to note that productive HSV infections have
been reported to alter the phosphorylation state of some
splicing factors (Sandri-Goldin and Hibbard, 1996). Per-
haps more relevant, recently published results showed
that ICP27 interacts with the  subunit of casein kinase
2 (CK2) in the yeast two-hybrid system, and CK2 activity
coimmunoprecipitates with ICP27 from extracts pre-
pared from HSV-infected cells (Wadd et al., 1999). It is
thus tempting to speculate that ICP27, via CK2, inacti-
vates essential splicing factors by phosphorylating them
at critical sites. Another possible mechanism by which
splicing is inhibited in the presence of ICP27 may be that
ICP27 physically binds to mRNA (both intron containing
and intronless) and thereby prevent the mRNA from be-
ing spliced. In support of this hypothesis we have found
that pre-mRNA co-immunoprecipitates from ICP27 ex-
tracts (data not shown). We believe that a trans-inhibiting
model (i.e., where ICP27 inhibits splicing via an enzy-
matic activity) and a cis-model (where ICP27 inhibits by
binding to pre-mRNAs) are not mutually exclusive.
Almost all previously published in vivo and in vitro
studies of ICP27 have relied on comparison of mRNA
accumulation in cells, or extracts from cells, infected with
wild-type or ICP27 mutated HSV viruses. Since many E
genes and all L HSV genes are dependent on ICP27 for
their expression, it is difficult to determine what is a
direct effect and what is an indirect effect by ICP27. For
instance, the in vitro splicing inhibition observed in ex-
tracts from HSV-infected cells could have resulted from
any viral protein that is dependent upon ICP27 for its
expression. Also, it is well established that cells have
antiviral defense systems, which sense an invading virus
and react by shutting down several biosynthesis pro-
cesses, such as translation. The possibility can therefore
not be formally excluded that such shutdown processes
may affect splicing as well. To the best of our knowledge
this is the first time it has been proven in vitro that the
presence of ICP27, in the absence of other HSV proteins,
inhibits splicing.
Which splicing factor(s) then, is the target(s) for the
splicing inhibition in ICP27-containing extracts? As pre-
viously mentioned, our in vitro splicing results indicate
that an essential splicing factor which is limiting for the
splicing process is affected in ICP27 extracts; we find
that it is sufficient to add splicing-competent extracts to
ICP27 extracts at a 1:3 ratio in order to substantially
restore splicing. Furthermore, our results show that the
ICP27-caused splicing inhibition is manifested at early
stages of spliceosome assembly, as shown by a reduced
rate of formation of the first ATP-dependent prespliceo-
some complex in ICP27 extracts. However, although the
rate of spliceosome formation was reduced at this stage,
the largest differences between ICP27 extracts and con-
trol extracts appeared to be in the rates at which the
mature spliceosomes (C complexes) were assembled.
This suggests that although the target(s) for ICP27-
caused splicing inhibition is present already at early
stages of spliceosome formation, its inability to function
properly in the ICP27 context is most apparent in the
transition from the prespliceosomal B complex to the
mature spliceosome. Potential targets for ICP27-caused
splicing inhibition were recently suggested by Soliman
and Silverstein (2000). They found that the C-terminal
part of ICP27 contains a motif which is present in Sm and
Lsm (Sm-like) proteins. Both Sm and Lsm proteins are
key parts of spliceosomal U snRNPs, which are essential
components of the spliceosomes. In addition to their role
in splicing, Lsm proteins have been found to play a role
in mRNA degradation (reviewed in He and Parker (2000)).
The putative Sm motif in ICP27 is located in the region
which is required for suppression of splicing, and Soli-
man and Silverstein proposed that ICP27 requires its Sm
motif to bind to the Sm complex and inactivate its func-
tion in splicing. This model would thus predict, as far as
we understand, that ICP27 inhibits splicing by titrating
out Sm proteins. We believe that nothing in the data
presented in this study supports or contradicts Soliman
and Silverstein’s proposed model for ICP27-caused
splicing inhibition.
We are currently developing a complementation assay
based on fractionated HeLa cell nuclear extracts in order
to identify splicing factors which are sufficient and es-
sential to restore splicing activity in ICP27 extracts. Pre-
liminary results from these studies show that a family of
splicing factors, the SR-proteins, are not capable of re-
versing the splicing inhibition in ICP27 extracts (data not
shown). The SR-proteins are the main targets for adeno-
virus-mediated inhibition of cellular pre-mRNA splicing
(Kanopka et al., 1998). It thus appears that, although HSV
and adenovirus attack the same cellular process, i.e.
splicing, they have evolved different systems, which are
directed against different components of the splicing
machinery. This makes sense since whereas adenovirus
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is highly dependent on splicing of its pre-mRNAs (only 1
of approximately 40 different mRNAs is generated from
an intronless gene), most HSV genes are intronless.
Whereas adenovirus favors its own growth at the host
cell’s expense by modulating the splicing machinery to
splice viral pre-mRNAs, HSV appears to attack an essen-
tial splicing factor(s) and thereby cause a complete shut-
off of splicing. For this reason we believe that identifica-
tion of the factor(s) that is targeted by ICP27 could be of
general importance since it may target previously un-
characterized parts of the splicing machinery.
During preparation of this article, J. B. Clements and
co-workers reported that ICP27 interacts with the essen-
tial splicing factor SAP145 during an HSV infection (see
Bryant et al., 2001). SAP145 is a component of the SF3b
particle, which is implicated in tethering U2 snRNP bind-
ing to the branch site and is thus needed at early stages
of spliceosome formation. Their findings thus support




The ICP27-expressing recombinant adenovirus
AdG5Trip(His)-ICP27 Lac (referred to as Ad5-ICP27 in
text) was constructed as follows. A BstYI fragment con-
taining ICP27 coding sequences was inserted into
the BamHI site in transfer plasmid pAdG5Trip(His)-Lac
Bam (Edholm et al., 2001), generating the transfer plas-
mid pAdG5Trip(His)-ICP27 Lac. Three micrograms of
AdG5Trip(His) ICP27 Lac was transfected into 293LacI
cells together with 1 g DNA from adenovirus mutant
dl309. The transfected cells were overlaid with DMEM/
agar. Virus plaques were isolated and purified. Recom-
binant viruses were verified by restriction enzyme cleav-
age of Hirt extracted viral DNA (Hirt, 1967). One plaque
containing the full-length ICP27 gene was selected and
purified by a second round of plaque assay. High-titer
stocks of AdG5Trip(His) ICP27 Lac were prepared es-
sentially as described by Hitt et al. (1994) and the virus
titer (FFU) was determined in 293 cells. The activator
virus AdCMVProg has previously been described (Molin
et al., 1998).
Expression of ICP27 in HeLa spinner cells
HeLa spinner cells were grown in spinner medium
containing 5% newborn calf serum to approximately 5 
105 cells/ml before being harvested by centrifugation.
The medium was removed and cells were suspended in
1/10 of the original culture volume and infected with
transactivator virus AdCMV Prog and Ad2-ICP27. After a
1-h incubation at 37°C, the remainder of prewarmed
spinner medium and calf serum was added, and ICP27
expression was induced by addition of RU486 (final con-
centration was 0.5 M). After 24 or 48 h of induction,
cells were harvested by centrifugation and nuclear ex-
tracts were prepared as previously described (Kreivi et
al., 1991) and the cytoplasmic fraction was used to pre-
pare S100 extract as described in Dignam et al. (1983).
Nuclear extracts from mock-infected cells and/or non-
induced Ad5-ICP27-infected cells were prepared in
parallel.
Immunoblotting
Proteins were separated by 10% SDS–PAGE and trans-
ferred to nitrocellulose membranes using a semidry
transfer apparatus. The filter was blocked with TBS
buffer (20 mM Tris, pH 7.5, 150 mM NaCl) containing 2%
dry milk. Primary antibodies were monoclonal anti-ICP27
(ABI) or sheep polyclonal anti-p99 (Kreivi et al., 1997).
Secondary antibodies were either horseradish peroxi-
dase-conjugated anti-mouse or anti-sheep antibodies.
Between ICP27 and p99 probing, the filter was stripped
with 100 mM -mercaptoethanol, 2% SDS, and 62.5 mM
Tris, pH 6.8, at 50°C for 30 min. Detection utilized a
chemiluminescent substrate followed by exposure on
Biomax MR film (Amersham Pharmacia Biotech).
In vitro splicing and in vitro transcription
The total splicing reaction volume was 20 l and
contained a 32P-labeled Ad1 (Konarska and Sharp, 1987)
or -globin (Muhlemann et al., 2000) pre-mRNA substrate
(50,000 cpm/reaction), 1.5 mM MgCl2, 40 mM KCl, 20 mM
creatinephosphate, 2 mM ATP, 15 U RNasin, 12 mM
HEPES, pH 7.9, and 40% (vol/vol) nuclear extract. RNA
polymerase II transcription was done essentially as de-
scribed in Martinez et al. (1994). Briefly, a SmaI fragment
encompassing the adenovirus major late promoter was
incubated together with nuclear extracts in the presence
of 32P-labeled CTP. The splicing reactions and the RNA
polymerase II products were incubated at 30°C for 1 h if
not otherwise stated, before RNA was isolated and an-
alyzed on 10% polyacrylamide gel, followed by autora-
diography. Dried gels were exposed to 32P-sensitive
phosphorimager screens and scanned on a phosphorim-
ager from Bio-Rad (GS-250). Splicing efficiency and RNA
polymerase II transcription were calculated by volume
integration of appropriate RNA signals.
Analysis of spliceosome assembly
For analysis of spliceosome assembly, 20-l in vitro
splicing reactions, using 32P-labeled Ad1 pre-mRNA as
substrate, were incubated at 30°C. At the indicated time
points, the in vitro splicing reactions were stopped by
transfer of the tubes to ice. Ten microliters of the reac-
tions was removed for analysis of splicing products as
described above. Heparin was immediately added to the
remaining half of the reactions and all of it was loaded on
a 3.5% (60:1) native polyacrylamide gel. The gel and
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running buffer were 75 mM Tris/glycine and the gels
were run at 350 V for 4 h. Gels were dried and complexes
were detected by autoradiography. The relative accumu-
lations of various spliceosomal complexes were quanti-
fied by phosphorimager analysis on a Bio-Rad phospho-
rimager (GS-250).
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